Share This Special Issue

Special Issue Editors

Special Issue Information

Dear Colleagues,

Glaucoma surgery still represents a real challenge both in terms of ensuring safety and efficacy, and particularly the balance between the two. Significant technological advances have led to innovative surgeries,which have in turn been rapidly introduced into clinical practice. New devices to lower intraocular pressure show promising results, but it is still unclear whether they can replace the current ‘standard’ surgeries, such as trabeculectomy or glaucoma drainage devices. Moreover, even these standard procedures are being continuously modified in various ways in the search for better safety and efficacy outcomes. At the same time, more and more attention is being paid to the ocular surface. It is well known that glaucoma-therapy-related ocular surface disease can worsen patients’ quality of life and affect the outcome of glaucoma filtration surgery. This is the reason for this Special Issue, for which we welcome manuscripts on the following topics:

Minimally invasive glaucoma surgery;
Minimally invasive bleb surgery;
Non-plate, bleb-forming glaucoma devices;
Trabeculectomy;
Glaucoma-therapy-related ocular surface disease;
Glaucoma drainage devices;
Non-penetrating glaucoma surgery;
Ciliary body function modulation;
Selective laser trabeculoplasty.

It is our pleasure to invite you to contribute to the Special Issue entitled "Advances in Glaucoma Surgery: 2nd Edition". This is one new edition, and we published 23 papers in the first edition. For more details, please visit: https://www.mdpi.com/journal/jcm/special_issues/glaucoma_surgery_clinical.

Prof. Dr. Michele Figus
Dr. Karl Mercieca
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Related Special Issue

Published Papers (1 paper)

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

13 pages, 1363 KiB

Open AccessArticle

Steroids and/or Non-Steroidal Anti-Inflammatory Drugs as Postoperative Treatment after Trabeculectomy—12-Month Results of a Randomized Controlled Trial

by Afrouz Ahmadzadeh, Line Kessel, Bo Simmendefeldt Schmidt, Miriam Kolko and Daniella Bach-Holm

J. Clin. Med. 2024, 13(3), 887; https://doi.org/10.3390/jcm13030887 - 02 Feb 2024

Viewed by 566

Abstract

This prospective randomized controlled trial aimed to compare the efficacy and safety of topical preservative-free diclofenac (DICLO) to dexamethasone (DEX) eyedrops, and their combination (DEX+DICLO) after trabeculectomy. Sixty-nine patients with medically uncontrolled glaucoma were randomized to receive topical postoperative treatment with DICLO (n = 23), DEX (n = 23), or a combination of DEX and DICLO (n = 23). The primary outcome was the intraocular pressure (IOP) 12 months postoperatively. Secondary outcomes included surgical success, failure, visual field, and visual acuity from baseline to 12 months postoperatively. IOP reached the lowest point one day after trabeculectomy. At 12 months, IOP was 10.0 mmHg (95% CI, 8.4–11.6 mmHg) for DICLO, 10.9 mmHg (95% CI, 9.4–12.3 mmHg) for DEX, and 11.2 mmHg (95% CI, 9.1–13.3 mmHg) for DEX+DICLO. There were no significant differences in IOP, surgical success, failure, visual field, or visual acuity between the DICLO, DEX, or DEX+DICLO groups. We found that topical diclofenac was not statistically different from topical dexamethasone in controlling IOP 12 months after trabeculectomy. Combining diclofenac and dexamethasone offered no added IOP control compared to dexamethasone alone. Full article

(This article belongs to the Special Issue Advances in Glaucoma Surgery: 2nd Edition)

► Show Figures

Journal Menu

Journal Browser

Advances in Glaucoma Surgery: 2nd Edition

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Related Special Issue

Published Papers (1 paper)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI